|Bid||3.2200 x 1400|
|Ask||3.3100 x 1200|
|Day's Range||3.2000 - 3.3400|
|52 Week Range||2.5200 - 54.6000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 12, 2020 - Aug 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
PRINCETON, NJ / ACCESSWIRE / August 4, 2020 / Sonnet BioTherapeutics Holdings, Inc.
PRINCETON, NJ / ACCESSWIRE / August 4, 2020 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has executed a letter of intent to negotiate an agreement to license its SON-081 and SON-080 assets, both low-dose formulations of Interleukin 6 (IL-6), for diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) to New Life Therapeutics Pte. Ltd. ("New Life") of Singapore.
* Data provide proof-of-concept for advancing SON-2014, a bispecific combination of GMcSF and IL-18 * The company will further explore the utility of a bispecific combination of GMcSF and IL-12PRINCETON, NJ / ACCESSWIRE / July 20, 2020 / Sonnet BioTherapeutics Holdings, Inc.